TIMI 15A evaluated the pharmacodynamic response, safety and pharmacokinetics of various doses of the GP IIb/IIIa inhibitor RPR 109891 given intravenously for the treatment of patients with acute coronary syndromes. MAIN RESULTS: First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI … Continue reading TIMI 15A